Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-99282 in relapsed or refractory non-Hodgkin lymphoma
NCT03930953Phase 2Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- May 2019
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, open-label trial of golcadomide in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Celgene Corporation. Primary endpoints: Incidence of Adverse Events up to 4 years, Number of participants with laboratory abnormalities up to 4 years and 2 more. Started May 2019; status: active, not recruiting.
02
Drugs
golcadomide
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03930953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03930953.